Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce Cree, Eliezer Katz, Jeffrey L. Bennett et al.|The Lancet|2019Cited by 722
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosisLauren Talman, Laura J. Balcer, Amy Conger et al.|Annals of Neurology|2010Cited by 365
Placebo-controlled study in neuromyelitis optica—Ethical and design considerationsBruce Cree, Eliezer Katz, Jeffrey L. Bennett et al.|Multiple Sclerosis Journal|2015Cited by 72
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum DisorderRomain Marignier, Bruce Cree, Jeffrey L. Bennett et al.|Neurology Neuroimmunology & Neuroinflammation|2021Cited by 42
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderRomain Marignier, Bruce Cree, Sean J Pittock et al.|Multiple Sclerosis and Related Disorders|2021Cited by 37